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Aims: To assess the efficacy and safety of once-weekly omarigliptin as monotherapy in
people with type 2 diabetes mellitus (T2DM).
Methods: People with T2DM not on glucose-lowering medications, or who were washed off
monotherapy or low-dose dual therapy, were randomized double-blind to omarigliptin 25
mg (n = 165) or matching omarigliptin placebo (n = 164) for 24 weeks, followed by a 30-week
period to assess continuing efficacy and safety longer-term of omarigliptin during which
metformin was added to the placebo group and metformin placebo to the omarigliptin
group.
Results: From a mean baseline HbA1c of 8.0–8.1%, the least squares mean (95% CI) change
from baseline in HbA1c at week 24 (primary endpoint) was 0.49% (0.73, 0.24) in the
omarigliptin group and 0.10% (0.34, 0.14) in the placebo group, for a between-group dif-
ference of 0.39% (0.59, 0.19) (p < .001). Protocol deviation in use of metformin by 38 of
252 (15%) people whose samples were available for evaluation probably attenuated glyce-
mic efficacy results, as suggested by the LSmean difference 0.53% (0.75, 0.32) after cen-
soring of such participants. At 24 and 54 weeks, the incidences of adverse events (AEs) were
similar in the omarigliptin and placebo groups. During 54 weeks there were no AEs of
symptomatic hypoglycemia in the omarigliptin group and 5 AEs in the placebo group. Over
54 weeks, a majority of the omarigliptin treatment had a persistent reduction in HbA1c,
remaining rescue-free.
Conclusions: In people with T2DM, omarigliptin monotherapy improved glycemic control
over 54 weeks and was generally well tolerated with a low risk of hypoglycemia.
ClinicalTrials.gov Identifier: NCT01717313.
EudraCT Number: 2012-003626-24.
 2017 Merck Sharp & Dohme Corp., and The Authors. Published by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Omarigliptin (MK-3102) is a selective, oral dipeptidyl
peptidase-4 (DPP-4) inhibitor with a half-life that enables
once-weekly dosing [1] that is presently approved in Japan.
In a phase 2 dose-range finding study [2], as monotherapy
[3] and in combination with metformin [4], omarigliptin had
comparable glucose-lowering efficacy to daily sitagliptin.
Experience of oral weekly glucose-lowering therapies in type
2 diabetes (T2DM) is very limited, and raises issues of adher-
ence and safety/tolerability.
We have therefore examined the efficacy and safety of
omarigliptin in a phase 3 clinical trial, using standard
double-blind, randomized, parallel group, placebo-controlled
methodology, with an extension phase to provide additional
exposure for safety purposes and to confirm maintenance
of efficacy. Because the glycemic efficacy at the primary end-
point (week 24) was less robust than that observed in other
omarigliptin trials, a series of investigations were undertaken
that uncovered the off-protocol use of metformin by some
trial participants. Metformin use was prohibited by protocol
except as investigator prescribed rescue medication. Protocol
violations in the use of metformin are likely to have affected
the trial results. We note the potential for this to be an issue
in other studies.
2. Methods
2.1. Study population
Eligible participants were men or women, 18 years of age
with T2DM, who at screening were either not on an oral
glucose-lowering drug (OGLD) for at least 12 weeks and had
a screening visit HbA1c 7.0% (53 mmol/mol) and 10.0%
(86 mmol/mol) on diet and exercise alone, or had HbA1c
6.5% (48 mmol/mol) and 9.0% (75 mmol/mol) on OGLD
monotherapy or low-dose (50% of maximum label dose of
each agent) dual oral therapy. Details of inclusion/exclusion
criteria, including excludedmedications, are given in the Sup-
plementary Appendix.
2.2. Study design
This was a multicenter, double-blind, randomized, parallel-
group trial. The duration of the trial was up to 65 weeks with
12 visits (Supplemental Fig. 1). This trial included a 1-week
screening period; an 8-week diet/exercise and oral agent
‘‘wash-off” (for people using OGLDs) period; a 2-week single-
blind placebo run-in period; a 24-week placebo-controlled,
double-blind treatment period (phase A); and a 30-week
active-controlled, double-blind treatment period (phase B).
Use of other OGLDs was prohibited before the primary end-
point at the end of the 24-week treatment period, except for
rescue therapy (see below). At or within 2 weeks prior to week
2, all eligible participants were required to have HbA1c
7.0% (53 mmol/mol) and10.0% (86 mmol/mol), and all were
required to have a fasting finger-capillary plasma glucose
<14.4 mmol/L at the time of randomization. Randomization
was to omarigliptin 25 mg once weekly (q.w.) or matching pla-
cebo for 24 weeks (phase A).At the end of phase A (the primary time point), participants
entered the 30-week extension period (phase B), in which
those randomized to placebo andwhowere not previously res-
cued with open-label metformin had blinded metformin
added to their treatment regimen to avoid prolonged ‘treat-
ment’ with placebo alone. Metformin was started at 500 mg
twice daily and up-titrated to 1000 mg twice daily. Omariglip-
tin was continued in those randomized to it, and blindedmet-
formin placebo added unless metformin had already been
begunas rescue therapy. Participants onopen-labelmetformin
rescue therapy remained in the trial throughout phase B.
During the trial, participants who did not meet progres-
sively stricter protocol-specified glycemic thresholds were
given rescue therapy (see Supplementary Table 1 for glycemic
thresholds). Prior to week 24, participants were rescued by
adding open-label metformin and after that time by adding
open-label glimepiride.
A meal tolerance test (MTT) was conducted at randomiza-
tion, before beginning trial medication, and at week 24 (or at
rescue/discontinuation visit) up to 7 days after the last dose of
omarigliptin, in participants from a subset of trial sites (see
Supplemental Appendix).
The study (Merck protocol MK-3102-011) was conducted in
accordance with Good Clinical Practice and the principles of
the Declaration of Helsinki and was approved by the regula-
tory agencies and appropriate institutional review boards/
ethics committees. Written informed consent was obtained
from all study participants.
2.3. Study evaluations and endpoints
The primary objectives of this study were assessment of the
efficacy, safety and tolerability of omarigliptin compared with
placebo when used as monotherapy. The primary study
hypothesis was that after 24 weeks of treatment, omarigliptin
25 mg once weekly would provide a greater reduction from
baseline in HbA1c than treatment with placebo. Secondary
objectives were to assess the effect of omarigliptin compared
with placebo on FPG, on the proportion of participants achiev-
ing HbA1c of <7.0% (53 mmol/mol), and on 2-h post-meal
plasma glucose (2-h PMG). Efficacy endpoints were change
from baseline in HbA1c, FPG and 2-h PMG. Blood samples
for omarigliptin population PK were collected at designated
visits and time points (see Supplementary Appendix). Analyt-
ical methods are given in the Supplementary Appendix. Data
will be reported in a separate publication.
Safety/tolerability assessment included collection of
adverse events (AEs), physical examination and vital signs,
blood chemistry, amylase, lipase, lipids, and hematology, uri-
nalysis, body weight, and electrocardiogram (ECG). A ques-
tionnaire was provided to participants to collect data on
hypoglycemia. Potential cases of pancreatitis (events
assessed by the investigator as possibly being pancreatitis
or events meeting prespecified event terms suggestive of pan-
creatitis) and prespecified hypersensitivity AEs (anaphylactic
reaction, angioedema, asthma-bronchospasm, erythema
multiforme, Stevens-Johnson syndrome, toxic epidermal
necrolysis, and drug rash with eosinophilia and systemic
symptoms) were evaluated blind to randomized treatments
by external clinical adjudication committees.
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For efficacy analyses, the population of all randomized partic-
ipants who received at least one dose of study treatment and
had a baseline or a post-randomization measurement served
as the primary population. For analyses of glycemic end-
points, a longitudinal data analysis (LDA) model [5], including
terms for treatment, time, prior AHA therapy status, and the
interaction of time by treatment, and time by prior AHA ther-
apy status, with the restriction of a common baseline mean
across treatment groups (valid through randomization), was
used. Analysis of percentages of populations at the HbA1c
goal of <7.0% (53 mmol/mol) at week 24 was based on esti-
mated rates and confidence intervals for between-group rate
differences computed using the Miettinen and Nurminen
method [6]. Multiple imputations based on the LDA model
used for the analysis of HbA1c were used to handle missing
data [7].
For the analysis of safety data, the population of all ran-
domized patients who received at least one dose of study
treatment was used. Safety and tolerability were assessed
during the treatment period and for 21 days after treatment
ended. AEs of symptomatic hypoglycemia were prespecified
as events of interest and p-values and 95% confidence inter-
vals (CI) for between-treatment group comparisons of inci-
dence were calculated. Change from baseline in body
weight was analyzed using the LDA model described above.
The primary analyses for both efficacy and safety censored
data acquired after beginning rescue therapy to avoid the
confounding effects of rescue therapy. A secondary analysis
was performed including data after rescue.
As defined in the statistical analysis plan, only observa-
tional comparisons of omarigliptin with metformin were
made in phase B, since metformin treatment was expected
to be imbalanced by the end of the primary phase due to
asymmetric use of it as rescue therapy. In addition, the pla-
cebo group switched to metformin at entry into phase B
was no longer the intact group randomized at the beginning
of the base period.
Using a conditional standard deviation (SD) for HbA1c
change over time of 1.0% (10.9 mmol/mol) in an analysis
model with baseline as a covariate, an effective sample size
of 135 subjects per treatment group at week 24 was calculated
to provide 90% power to detect a true difference of 0.40% (4.4
mmol/mol) in the mean change from baseline between the
two treatment groups (2-sided test, a = 0.05).
3. Results
3.1. Participant disposition and characteristics
In total, 751 people were screened with 422 excluded. The
most common reasons for screen failure were not meeting
the glucose-lowering therapy and HbA1c requirements, or
having exclusionary laboratory values. The remaining 329
people were randomized at 76 sites in 10 countries (Bulgaria
[10], Germany [36], Hungary [44], Italy [13], Netherlands [17],
Philippines [36], Romania [49], South Korea [12], Taiwan [40],
and United States [72]). The trial was begun in December2012 and the last participant visit at 54 weeks was in June
2015. Baseline characteristics were similar between the ran-
domized treatment groups, including prior use of glucose-
lowering therapies prior to wash-off (Table 1). Of the 329 peo-
ple randomized, 56.2% (185 people) had been treated with
metformin and 2.7% (9 people) had been treated with other
OGLDs prior to enrollment in the study and required wash-
off.
Of the 165 participants in the omarigliptin group, 89.1%
(147/165) completed phase A on trial medication, 88.5%
(146/165) entered phase B, 87.3% (144/165) completed the trial
through 54 weeks, and 73.3% (121/165) completed on trial
medication (Supplementary Table 2).
Of the 164 participants in the placebo group, 92.1%
(151/164) completed phase A on trial medication and entered
phase B; 83.5% (137/164) completed the trial through 54
weeks, and 77.4% (127/164) completed on trial medication.
Of the randomized population, in the omarigliptin group
at 24 weeks, 10.9% (18/165) had initiated rescue therapy, the
Kaplan-Meier estimate allowing for discontinuations being
11.9% (95%CI 7.7, 18.2). This compares to 15.2% (25/164) and
16.0% (95%CI 11.1, 22.8) for the placebo, not statistically signif-
icantly different from the omarigliptin group. At 54 weeks
these figures were 32.7% (54/165) and 37.7% (95%CI 30.3,
46.3) for the omarigliptin group and 23.2% (38/164) and
25.3% (95%CI 19.1, 33.2) for the placebo/metformin group.
3.2. Efficacy
3.2.1. 24-week placebo-controlled period (phase A)
From a mean baseline HbA1c of 8.0% (64 mmol/mol) in the
omarigliptin group and 8.1% (65 mmol/mol) in the placebo
group, the between-group difference in least squares (LS)
mean (95% CI) change from baseline in HbA1c at week 24
was 0.39% (0.59, 0.19) (4.3 mmol/mol [6.4, 2.1]);
p < .001 (Table 2). The estimated percentage (95% CI) of partic-
ipants at the HbA1c target of <7.0% (53 mmol/mol) was 36.5%
(29.3%, 44.5%) in the omarigliptin group, and 16.3% (11.3%,
22.5%) in the placebo group (p < .001 between groups).
The between-group difference in LS mean (95% CI) change
from baseline at week 24 in FPG was 0.6 (1.1, 0.0) mmol/L,
p = .036 (Table 2). For 2-h PMG this was 0.6 (1.6, 0.3) mmol/L
(Table 2).
3.2.2. 54-week period (phases A + B)
The LS mean (95% CIs) changes from baseline at week 54 in
HbA1c in the omarigliptin and placebo/metformin groups
were 0.40% (0.67, 0.13) (4.4 mmol/mol [7.3, 1.4]) and
0.80% (1.07, 0.53) (8.7 mmol/mol [11.7, 5.8]), (Supple-
mentary Table 3). The modeled profile of change in HbA1c
over time is shown in Fig. 1A. The estimated percentage
(95% CI) of people with HbA1c <7.0% (53 mmol/mol) in the
omarigliptin and placebo/metformin groups were 33.8%
(26.8%, 41.5%) and 43.8% (36.2%, 51.7%). The LS mean (95%
CI) changes from baseline to week 54 in FPG in the omariglip-
tin and placebo/metformin groups were 0.5 (1.1, 0.2)
mmol/L and 1.2 (1.8, 0.5) mmol/L (Supplementary
Table 3). The profile of change from baseline in FPG over time
is shown in Fig. 1B.
Table 1 – Baseline characteristics of the people with type 2 diabetes studied.
Omarigliptin Placebo
n = 165 n = 164
Age, years 57.4 ± 9.2 57.0 ± 9.7
Male, n (%) 95 (57.6) 97 (59.1)
Race, n (%)
White 113 (68.5) 111 (67.7)
Asian 47 (28.5) 43 (26.2)
Black 4 (2.4) 9 (5.5)
Multi-racial 0 (0.0) 1 (0.6)
American Indian/Alaska Native 1 (0.6) 0 (0.0)
Ethnicity, n (%)
Not Hispanic or Latino 162 (98.2) 162 (98.8)
Hispanic or Latino 3 (1.8) 2 (1.2)
Body weight, kg 87.6 ± 21.6 87.9 ± 23.2
BMI, kg/m2 31.1 ± 6.1 30.8 ± 6.6
HbA1c
% 8.0 ± 0.9 8.1 ± 1.0
mmol/mol 64 ± 10 65 ± 11
2-Hour PMG, mmol/L 14.2 ± 4.1 13.4 ± 3.8
FPG, mmol/L 9.6 ± 2.3 9.4 ± 2.4
Duration of diabetes, years 5.4 ± 3.8 5.7 ± 4.7
Prior OGLD therapy
None 74 (44.8) 61 (37.2)
Metformin user 87 (52.7) 98 (59.8)
Not-metformin user 4 (2.4) 5 (3.0)
Values are Mean ± SD or n (%).
BMI, body mass index; PMG, post-meal plasma glucose; FPG, fasting plasma glucose; OGLD, oral glucose-lowering drug.
Glucose in mg/dL = mmol/L  18.0.
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3.3.1. 24-week placebo-controlled period (primary phase A)
and 54-week period (phase A + B)
In both phase A and over the entire treatment period (phase
A + B), the percentage of patients with one or more adverse
event (AE), drug-related AE, serious AE, andwho discontinued
due to an AE were similar between treatment groups (Table 3).
There were no clinically meaningful between-group differ-
ences in the incidences of AEs by Medical Dictionary for Reg-
ulatory Activities (MedDRA) system organ class or any specific
AE in either treatment period, with the exception of the AE of
hypoglycemia as described below.
During phase A, AEs of hypoglycemia (symptomatic or
asymptomatic), excluding data after glycemic rescue, were
reported for 1 person (0.6%) in the omarigliptin group and
two (1.2%) in the placebo group (Table 3). The single AE of
hypoglycemia in the omarigliptin group was asymptomatic
(documented glucose level 3.9 mmol/L without symptoms);
the AEs in the placebo group were documented symptomatic
hypoglycemia. During phases A + B, the proportion of partic-
ipants with the AE of symptomatic hypoglycemia was signif-
icantly lower in the omarigliptin group (none) compared with
the placebo/metformin group (3.0% [5/164 people]; 4 of whom
had documented hypoglycemia) (Table 3). No severe hypo-
glycemia was reported in the study.
During phases A + B, no participants in either treatment
group had adjudication-confirmed pancreatitis (acute or
chronic). No one in the omarigliptin group and 1 person in
the placebo group had adjudication-confirmed asthma-bronchospasm. There were no other hypersensitivity reac-
tions (see Methods). There were no clinically meaningful
mean changes from baseline in laboratory measures (includ-
ing electrolytes, liver function tests, renal function measures,
serum lipids, and hematology, serum amylase or lipase), pre-
defined limits of change for laboratory measures, vital signs,
body weight (see Supplementary Table 4), or ECG parameters
in either treatment group.
3.4. Investigations into the attenuated glycemic efficacy
Given that the glycemic efficacy observed in this study was
attenuated compared with previous omarigliptin studies
(see Discussion) a series of investigations were undertaken
to determine if compliance with study medication, opera-
tional errors or other trial-related failings might have con-
tributed to the results. Compliance with study medication
(omarigliptin or matching omarigliptin placebo) was assessed
at each visit by patient report. During the primary 24 week
phase, mean compliance with study medication was 95.2%
in the omarigliptin group and 94.7% in the placebo group.
Over the 54-week treatment period, mean compliance with
study medication was the same (95.3%) in the two the treat-
ment groups.
No errors were identified in the distribution of study med-
ication based on reviews of the allocation schedule, interac-
tive voice recognition system (used to randomize subjects),
drug dispensing logs or drug supply records. Measurement
of omarigliptin concentrations, which were assessed in the
PK samples of subjects in both the omarigliptin and placebo
Table 2 – Glycemic endpoints at week 24.
Omarigliptin Placebo
Full study population (randomized and treated)
HbA1c (n = 165/164)
Baseline % 8.0 ± 0.9 8.1 ± 1.0
mmol/mol 64 ± 10 65 ± 11
Week 24a % 7.4 ± 1.1 7.8 ± 1.0
mmol/mol 57 ± 12 61 ± 11
Change from baselineb % 0.49 (0.73, 0.24) 0.10 (0.34, 0.14)
mmol/mol 5.3 [8.0, 2.7] 1.1 [3.7, 1.6]
Change vs. placeboc,d % 0.39 (0.59, 0.19) –
mmol/mol 4.2 (6.4, 2.1) –
FPG (n = 165/164), mmol/l
Baseline 9.6 ± 2.3 9.4 ± 2.4
Week 24a 8.5 ± 2.3 8.8 ± 2.3
Change from baselineb 0.7 (1.4, 0.0) 0.1 (0.8, 0.6)
Change vs. placeboc,e 0.6 (1.1, 0.0) –
2-h PMG (n = 106/102), mmol/L
Baseline 14.2 ± 4.1 13.4 ± 3.8
Week 24a 12.0 ± 3.8 11.9 ± 3.7
Change from baselineb 1.4 (3.1, 0.3) 0.8 (2.4, 0.9)
Change vs. placeboc 0.6 (1.6, 0.3) –
Per protocol population excluding users of prohibited metformin
HbA1c (n = 149/131),%
Baseline % 8.0 ± 0.9 8.0 ± 0.9
mmol/mol 64 ± 9.8 64 ± 9.8
Week 24a % 7.3 ± 1.1 7.8 ± 1.1
mmol/mol 56 ± 12.0 62 ± 12
Change from baselineb % 0.54 (0.68, 0.39) 0.00 (0.17, 0.16)
mmol/mol 5.9 (7.4, 4.3) 0.0 (1.9, 1.7)
Change vs. placeboc,d % 0.53 (0.75, 0.32) –
mmol/mol 5.8 (8.2, 3.5) –
FPG (n = 149/131), mmol/L
Baseline 9.7 ± 2.4 9.3 ± 2.3
Week 24a 8.4 ± 2.4 8.9 ± 2.4
Change from baselineb 0.9 (1.2, 0.5) 0.1 (0.6, 0.4)
Change vs. placeboc,f 0.7 (1.3, 0.2) –
2-h PMG (n = 95/80), mmol/L
Baseline 14.2 ± 4.1 13.3 ± 3.9
Week 24a 11.7 ± 4.0 11.6 ± 3.7
Change from baselineb 2.2 (3.0, 1.5) 1.1 (1.9, 0.3)
Change vs. placeboc,g 1.1 (2.2, 0.1) –
Unless noted, values are Mean ± SD.
PMG, post-meal glucose; FPG, fasting plasma glucose.
Plasma glucose mg/dl = mmol/l  18.0.
a Completers on randomized therapy.
b Least squares (LS) mean (95% CI).
c Difference in LS means (95% CI).
d p < .001
e p = .036
f p = .014
g p = .031
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omarigliptin were in the expected range, with 3.3% of samples
having no measurable drug (suggesting the possibility of a
missed dose).
Because off-protocol use of a prohibited medication, met-
formin, was found in another study in the omarigliptin phase
3 program [8], plasma samples drawn for the measurement of
PK at week 18 were assayed for metformin. Two hundred-seventy of the trial participants hadweek 18 pharmacokinetic
samples that were analyzable. Excluding the 18 people on
metformin rescue therapy, measurable levels of metformin
were found in 9.8% (12/123) of people in the omarigliptin
group and 20.2% (26/129) of people in the placebo group. Peo-
ple found to have off-protocol metformin were from the fol-
lowing countries (n): Germany (6), Hungary (13), Netherlands
(3), Philippines (3), Romania (6), Taiwan (5) and United States
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Fig. 1 – The trajectory of efficacy measures over the duration
of the study. (A) Least squares (LS) mean change from
baseline in HbA1c; (B) LS mean change from baseline in
fasting plasma glucose (FPG). d omarigliptin;  placebo/
metformin. Data derived from a longitudinal data analysis
model including terms for treatment, time, prior glucose-
lowering (OGLD) therapy status, and the interaction of time
by treatment, and time by prior OGLD therapy status, with
the constraint that the mean baseline is the same for all
treatment groups, and censoring for rescue. Baseline data
and statistical comparisons are given in Table 2.
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from the modified ITT population those taking prohibited
metformin. Here the omarigliptin-placebo difference was
larger for HbA1c than in the primary analysis, though with
no change for other glucose measures (Table 2).
4. Discussion
This study was designed to assess the efficacy, and obtain
safety data, for omarigliptin 25 mg once daily (q.w.) when
used as monotherapy in people with T2DM with inadequate
glycemic control on diet and exercise. Based on the prespeci-
fied primary and secondary analyses, the key trial hypotheses
and objectives of demonstrating that use of omarigliptin for
24 weeks provided significantly greater reductions frombaseline in HbA1c and FPG, compared with placebo, were
met. However, glycemic efficacy from a baseline HbA1c of
around 8.0% (64 mmol/mol) was less robust than anticipated
compared with other omarigliptin trials [2–4] and that
reported in the literature for daily DPP-4 inhibitors [9–17].
For example, the placebo-adjusted LS mean reduction from
baseline in HbA1c at week 24, 0.39% (0.59, 0.19) (4.3 mmol/mol
[6.4, 2.1]), compares to 0.71% (0.93, 0.50) (7.8 mmol/mol [10.2,
5.5]) at 12 weeks in the phase 2 dose-range finding trial from
similar baseline levels [2]. It is also at the lower end of the
range of changes in HbA1c reported from trials of once-
daily DPP-4 inhibitors conducted in similar patient popula-
tions with similar mean baseline HbA1c, where findings ran-
ged from 0.41% (4.5 mmol/mol) to 0.80% (8.7 mmol/mol) [9–
14].
The situation was similar for reduction in 2-h PMG, being
1.4 (3.1, 0.3) mmol/l absolute, but only 0.6 (1.6, 0.3) placebo-
adjusted at 24 weeks, from a mean baseline of 14.2 mmol/L,
against the placebo-adjusted reduction of 2.5 (3.3, 1.7)
mmol/l at 12 weeks in the phase 2 study [2]. The finding is
also at variance with reductions reported for once daily
DPP-4 inhibitors in the literature [9,11,14–16]. For fasting
plasma glucose the situation is a little different but not com-
pletely inconsistent. Thus again the findings in the current
study of a 0.6 (1.1, 0.0) mmol/L treatment difference are below
those of 1.3 (1.8, 0.9) mmol/L from a mean baseline of 9.7
mmol/L in the phase 2 study [2]. However, the placebo-
adjusted reduction in FPG observed in the current study is
consistent with the reductions reported in the literature for
daily DPP-4 inhibitors, where reductions in FPG from a mean
baseline of around 9.4 mmol/L ranged from 0.2 to 1.3 mmol/L
[9–13,17].
These glucose-lowering findings were also inconsistent
with the results of a phase 3 head-to-head comparison trial
of omarigliptin 25 mg q.w. and sitagliptin 100 mg once-daily,
in which the HbA1c-lowering of omarigliptin was not only
demonstrated to be non-inferior to sitagliptin, but the
changes in profile over time of HbA1c and FPG for omariglip-
tin and sitagliptin were essentially overlapping [4].
Neither the statistical modeling nor population changes
through drop-out or rescue therapy are likely explanations
of these unexpected results in the current study. Both discon-
tinuation from study and rescue before the primary endpoint
(week 24) affected only a small proportion of the randomized
population. The achieved HbA1c of the completer non-rescue
population at 24 weeks is just 0.60% (6.6 mmol/mol) below the
mean baseline level (Table 2). Similarly, although the reported
adherence to study medication (approximately 95%) was
slightly lower than that observed in other omarigliptin stud-
ies (98–99%), this is unlikely to result in a meaningful attenu-
ation in efficacy. Furthermore, analyses indicated that the
‘attenuated’ efficacy was not due to operational aspects of
the trial.
However, investigations into the use of prohibited met-
formin revealed that it was twofold more prevalent in the pla-
cebo group than the omarigliptin group, and to an extent that
would be expected to bias the primary results against omari-
gliptin. Indeed, a post hoc analysis that excluded participants
found to have prohibited metformin in a single plasma
sample showed a greater treatment effect (Table 2). Thus,
Table 3 – Adverse events (AE) summary for omarigliptin and placebo groups to week 24, and omarigliptin and placebo/metformin groups thereafter.
Participants, n (%) Phase A (to week 24) Phase A + B (to week 54)
Omarigliptin
n = 165
Placebo
n = 164
Difference (%)a Omarigliptin
n = 165
Placebo/metformin
n = 164
Difference (%)a
With one or more
AEs 69 (41.8) 82 (50.0) 8.2 (18.8, 2.6) 90 (54.5) 99 (60.4) 5.8 (16.4, 4.9)
Drug-related AEsb 4 (2.4) 3 (1.8) 0.6 (3.1, 4.5) 13 (7.9) 16 (9.8) 1.9 (8.3, 4.4)
Serious AEs 4 (2.4) 5 (3.0) 0.6 (4.8, 3.4) 5 (3.0) 8 (4.9) 1.8 (6.7, 2.7)
Serious drug-related AEsb 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0) –
Deathc 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0) –
Who discontinued due to
An AE 4 (2.4) 3 (1.8) 0.6 (3.1, 4.5) 5 (3.0) 4 (2.4) 0.6 (3.5, 4.8)
A drug-related AEb 1 (0.6) 1 (0.6) – 2 (1.2) 2 (1.2) –
A serious AE 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0) –
A serious drug-related AEb 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0) –
With 1 AE of hypoglycemia 1 (0.6) 2 (1.2) – 1 (0.6) 5 (3.0) 2.4 (6.4, 0.6)
Symptomaticd 0 (0.0) 2 (1.2) – 0 (0.0) 5 (3.0) 3.0g (6.9, 0.7)
Severee 0 (0.0) 0 (0.0) – 0 (0.0) 0 (0.0) –
Asymptomaticf 1 (0.6) 0 (0.0) – 1 (0.6) 0 (0.0) –
a Percent difference estimate (95% CI) was computed only if 4 participants had a relevant events in 1 treatment group.
b Assessed by the investigator to be related to the study drug.
c One person in the placebo group who died >21 days after their last documented dose of study medication is not included.
d Symptomatic hypoglycemia: episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level.
e Severe hypoglycemia: episode that required assistance, either medical or non-medical.
f Asymptomatic hypoglycemia: self-measured glucose values 3.9 mmol/L without symptoms.
g p = 0.024
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adjusted LS mean reduction from baseline in HbA1c of
0.39% (0.59, 0.19) (4.2 mmol/mol [6.4, 2.1]), the post hoc analy-
sis showed a between-group difference of 0.53% (0.75, 0.32)
(5.8 mmol/mol [8.2, 3.5]), which is consistent with the litera-
ture. However, this post hoc analysis is limited by the fact that
the prohibited metformin was only measured at one time
point, and it is unknown how long the participants took it,
nor if others had also used it earlier. Prohibited OGLDs other
than metformin were not assessed.
The randomized, double-blind, placebo-controlled clinical
trial design is considered the gold standard to assess absolute
drug efficacy, since the intrinsic safety and efficacy of any test
compound is best compared to placebo. However, placebo-
controlled approaches in people with T2DM have inherent
design features that lend themselves to the excess use of pre-
scribed, rescue, and prohibited additional glucose-lowering
therapies. The majority of participants in the current study
were washed off other glucose-lowering medications prior to
randomization, and self-monitoring of finger capillary glucose
was used to ensure that glucose levels remained safe in the
short term. This potentially leads to loss of the benefit of
concealed randomization, promoting the chances of rescue
and prohibited use of other medications, particularly in the
placebo group. Sources of the prohibited metformin might
include previous prescriptions (56.2% of participants had been
previously treatedwithmetformin), a ‘‘drop-in” effect inwhich
physicians other than the investigator prescribed metformin,
medication from other family members, and, where available,
over-the-counter metformin without prescription. We note
our findings may be relevant to many other studies of new
medications in diabetes, including some already published.
Our study continued out to 54 weeks. This was mainly for
the purposes of gathering more safety and tolerability data.
Because the randomization against placebo was lost by the
addition of metformin to that arm (in those not on it as rescue
therapy), the efficacy observations in the placebo/metformin
treatment group cannot be directly compared to the omari-
gliptin treatment group. However, despite the change in the
rescue threshold to an HbA1c of 8.0% (64 mmol/mol) at 30
weeks, only a further quarter of the population on omariglip-
tin was rescued between 24 and 54 weeks. The implication is
that a majority of the omarigliptin-treated population
achieved continuing efficacy.
In this trial, omarigliptin was generally well tolerated.
There was a very low incidence of hypoglycemia, consistent
with the glucose-dependent mechanism of action of DPP-4
inhibitors [18], and no severe hypoglycemia. There was also
no clinically relevant increase in body weight.
In summary, despite the use of prohibited metformin in
this study, which is likely to have biased the study against
the omarigliptin group, the HbA1c lowering with omarigliptin
at week 24 was clinically meaningful, and was maintained
over the remaining 30 weeks of the trial. The finding in this
trial of the use of prohibited medication highlights the poten-
tial problem of non-adherence to the protocol in clinical
research, which may be an underappreciated phenomenon
that can undermine the research endeavor. Participants act-
ing on their own, without knowledge of the protocol, and
without proper monitoring by investigators and trial staff,have the potential to affect trial results and lead to mischar-
acterization of a drug. An accurate assessment of the efficacy
of omarigliptin is best characterized by the efficacy observed
in multiple trials across the development program, including
the head-to-head study with the daily DPP-4 inhibitor sita-
gliptin [4], which suggests that the efficacy of omarigliptin is
similar to that of sitagliptin.Declarations
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